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Background: An in vitro procedure based on a microarray containing many different allergen components has
recently been introduced for use in allergy diagnosis. Recombinant and highly purified allergens belonging to different
allergenic sources (inhalants, food, latex and hymenoptera) are present in the array. These components can either be
genuine or cross-reactive, resistant or susceptible to heat and low pH, and innocuous or potentially dangerous. A large
number of complex and heterogeneous relationships among these components has emerged, such that sometimes
these interactions cannot be effectively managed by the allergist. In the 1960s, specialized languages and environments
were developed to support the replacement of human experts with dedicated decision-making information systems.
Currently, expert systems (ES) are advanced informatics tools that are widely used in medicine, engineering, finance
and trading.
Methods: We developed an ES, named Allergenius ®, to support the interpretation of allergy tests based on microarray
technology (ImmunoCAP ISAC ®). The ES was implemented using Flex, a LPA Win-Prolog shell. Rules representing
the knowledge base (KB) were derived from the literature and specialized databases. The input data included the
patient’s ID and disease(s), the results of either a skin prick test or specific IgE assays and ISAC results. The output
was a medical report.
Results: The ES was first validated using artificial and real life cases and passed all in silico validations. Then, the
opinions of allergists with experience in molecular diagnostics were compared with the ES reports. The Allergenius
reports included all of the allergists’ opinions and considerations, as well as any additional information.
Conclusions: Allergenius is a trustable ES dedicated to molecular tests for allergy. In the present version, it provides a
powerful method to understand ISAC results and to obtain a comprehensive interpretation of the patient’s IgE profiling.
Keywords: 3 TO 10 DIFFERENT ImmunoCAP ISAC, Allergen microarray, Artificial intelligence, Expert system, ISAC
interpretation, Genuine component, Cross-reactive component, Computer supported diagnosisBackground
The availability of microarrays (MA) of recombinant or
highly purified allergenic components has significantly
improved the study of the IgE repertoire [1]. This is of
particular relevance in poly-sensitized patients [2], in
which up to 50% of the treatments can benefit from this
approach [3]. Moreover, molecular analysis of the sensi-
tizations allows for the refinement of the prescription of
a specific immunotherapy [4,5] and a prediction of an* Correspondence: giovannimelioli@gmail.com
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unless otherwise stated.outcome for the immunotherapy treatment [6]. However,
the interpretation of the MA reports is sometimes a dif-
ficult task [7]. Indeed, according to their molecular
characteristics, the components can be divided into
inhalants or food, seasonal or perennial, genuine or
cross-reactive, heat, pH and peptidase resistant or
susceptible, innocuous or dangerous, causing local or
systemic effects, etc. The relationships between all of
these characteristics are complex [8]. For this reason,
the professionals need to be trained, and a comprehensive
approach in preparing and explaining the reports is re-
quired [7]. In recent years, two generations of allergen MA
(the first with 103 and the second with 112 components)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Milano, Italy). These tools have been extensively validated
in different clinical settings [9-11]. The recent 112 compo-
nent version may include a specialized report, generated
by the X-Plain ® software, that explains the nature of the
positive components. However, although this is sufficient
for the management of a majority of the cases, it is not
completely suitable for complex patients.
The information needed to interpret an ISAC report is
available in specialized literature, and the knowledge in
this field is rapidly progressing. Computer-supported
diagnosis (CSD) tools, based on expert systems (ESs),
were developed in the 1960s and have been used in the
past to support clinical routines [12-16]. At present, ESs
are deeply integrated in many informatics tools, including
medicine, finance, trading, engineering, social network
analysis and web research engines. By definition, ESs are a
part of the artificial intelligence (AI) world; however,
because they belong to the knowledge-based systems,
ESs are not considered auto-learning tools. They are
intended to act as human experts consulted to obtain
advice, suggestions and recommendations on problems
that fall within the experts’ knowledge [17]. Thus, during
the development of an ES, the external consultants indi-
cate both the objects that are involved and the rules
that govern these objects [18]. Certainly, the continuous
update of knowledge, based on the experts’ experience
and on scientific improvements, allows for a real-time
maintenance of the objects and rules.
Practically, ESs are composed of three independent
structures: the experts’ knowledge base (KB), the infer-
ential engine (IE) that manages the set of rules, and the
interface with the outside world (I/O). The IE works
even if the KB is significantly modified, allowing the KB
to be largely independent from the IE. For all of these
reasons, MA interpretation seems to be a natural challenge
that can benefit from an artificial intelligence approach.
To design and implement such an ES, we first analyzed
how molecular allergy experts extract the relevant data
from an ISAC report. Additionally, we identified what
additional information that is not immediately available
in the report can be obtained from a comprehensive
interpretation of the ISAC results. In this report, we
describe the structure and validation procedures of an
ES developed for the interpretation of ISAC results.
Methods
Collection of information
Definitions were used according to the literature [7,8].
The KB and the rules were derived from published data
[19], the authors’ experience [4,10,11] and the experts’
opinions. Specific information on the components was
obtained from the Allergome [20], Allergen online [21],
RCSB [22], Uniprot [23] and the WHO/IUIS AllergenNomenclature websites [24,25]. The cross-reactive com-
ponents were ordered into families [26]. The allergen- or
component-associated clinical pictures, such as the pollen-
food syndromes were also considered [19,27,28]. Finally,
the rules for the classification of the phenotypes [29] and
strategies for the prescription of allergen specific immuno-
therapies [3-6,30-32] were also implemented.
Construction of the ES structure
The ES code was written using Flex, an advanced Know-
ledge Specification Language (LPA, London UK). This ES
environment was chosen because it is suited to symbolic
problems, rather than numerical ones. Flex is written in
plain English, which allows non-professional programmers
to update the code. Functionally, the ES is based on
frames (representing the KB), rules that drive the system
itself and I/O structures.
Knowledge bases
The frames containing facts were based on a classic
hierarchical structure. They contained the 112 ISAC
components (Phl p1, Der p 2, etc.) and their attributes,
such as class (inhalant, food, venom, latex), group (mites,
trees, etc.), origin (Betula v., Olea e., etc.), nature (genuine,
cross-reactive), family (PR-10, nsLTP, profilin), sub-family
(prolamin, etc.) and molecule (alpha-amylase, gliadin-
omega-5, etc.). Additionally, the component frequency,
median value, maximum value and 97.5 percentile (in
ISU), resistance to heat, acid pH and peptidase and
comment(s) including specific references were also added.
This frame structure is extremely efficient because it can
be easily modified to update or change the information
without affecting the governing rules.
Input/output structures
This interface allows for the addition of the patient's
personal and clinical data, including the results of the
ISAC and other assays, such as SPT and sIgE, to the ES.
The language (English or Italian) and the level of detail
in the report (basic or advanced) can also be defined by
the user.
Rules
More than 700 different rules were implemented to mimic
the experts’ opinions on a complex ISAC result. The rules
were classified as top, intermediate and low level rules, on
the basis of the impact that each rule has on the decision
tree. An example of these rules is presented in Table 1.
The inference engine (IE)
The IE is the core of the ES and manages the data of the
hierarchical structure of the KB frames. This allows the
analysis of all components (both single allergens and
allergen families) using an iterative approach. Briefly,
Table 1 Rules implemented in the expert system Allergenius
Top level rules (examples)
1. IgE specific for a given allergen or component are signs of sensitization. Specific IgE and relevant clinical signs are indicative of an allergy.
2. Inhalant allergens are either genuine or cross-reactive.
3. Microarray allergens are classified as inhalants, food, contacts or venoms.
4. Allergens are classified as innocuous or potentially dangerous [8].
5. Components are classified as recombinant molecules (without glycidic chains, such as rPhl p 1) or highly purified extractive molecules
(containing glycidic chains, such as nCyn d 1).
6. Relationships between microarray components and allergens:
a) A positive component is generally associated with the positivity of the relevant allergen (e.g., der p 1 and D1 are positive).
b) Negative components are generally associated with the negativity of the relevant allergen (e.g., Der p 1, Der p 2, Der p 10, Der f 1 and
Der f 2 are negative, as well as D1).
c) Negative components are sometimes associated with a positive allergen (e.g., Der p 1, Der p 2, Der p 10, Der f 1 and Der f 2 are
negative and D1 is positive). However, the frequency of these cases is known [10], and the allergen score is generally very low.
d) If one or more components are positive but the relevant extractive allergen is negative, the rare, and at least partially unexpected,
discrepancy should be clearly reported.
Intermediate level rules (examples)
1. When > 40% of the components of a family of cross-reactive components are positive, a positivity towards the whole family must be
considered [18].
2. Immunotherapy is more active if sensitization to one or a few genuine components is observed [5,6].
3. More than three different families of allergens cannot be administered to the patients [30,31].
4. According to the ratio between the genuine and cross-reactive components, different phenotypes are identified [29].
Low level rules (examples)
1. Very low levels of a component associated with a very high level of IgE to a cross reactive component are most likely associated with a
cross reaction between the components. This positivity is trustable only if the clinical signs associated with sensitization to these low level
IgE components are evident. (for example: Lep d 2 is weakly positive, and Der f 2 is strongly positive; a cross reaction, at least in the in vitro
test, should be suspected based on the > 50% identities in the primary structures).
2. When a component is negative (e.g., Amb a 1) and the extractive allergen (Ambrosia a.) is positive, if all other cross-reactive components
(such as profilins, PR-10, polcalcins) are also negative, even if belonging to other allergens, a real discrepancy is reported. The frequency of
this discrepancy is calculated and shown in Allergenius, as well as the median score of ImmunoCAP for this category of allergens.
Melioli et al. World Allergy Organization Journal 2014, 7:15 Page 3 of 9
http://www.waojournal.org/content/7/1/15using the I/O routines, the IE acquires the patient’s
ISAC results and elaborates these results to obtain fur-
ther data (Table 2). The IE elaboration is based on both
forward chaining rules (i.e., knowing the data, one single
expected result is obtained, a data-driven reasoning) and
backward chaining relations (i.e., knowing the effect, one
or more pre-existing conditions are provided, a goal-
driven reasoning). Starting from all these data and from
the reasoning strategies implemented, the IE checks the
consistency between the components, the sIgE or SPTTable 2 Data used or calculated by the inference engine (IE)
1) Single components, such as Der p 1 or Der p 2, in ISU.
2) Single source allergens, corresponding to the sum of the components, suc
3) Comprehensive source allergens (such as Der f 1, Der f 2 and Der p10 – a
the ISAC panel).
4) Cross-reactive families (such as tropomyosins, represented by Ani s 3, Bla g
5) Allergen groups (such as mites, grasses and trees), represented by the sum
6) Enlarged component groups (such as inhalants, food, latex and Hymenop
belonging to those large groups.
7) The total amounts of the scores for either genuine or cross-reactive inhalatest results and the declared allergic disease(s). In this
context, a low level management of uncertain (or un-
known) SPT or sIgE data are also performed. Then, the
IE comments on the frequency of the sIgE profile ob-
served, ranging from a frequent, in which the patients are
sensitized to one or more components belonging to the
well-defined allergen families, to more rare situations
when few positive scattered components are observed.
According to the level of the detail required, the IE adds
the information related to the component characteristics,h as Der f 1 and Der f 2 for Dermatophagoides pt.
component highly homologous to the Der f 10 that is not included in
7, Der p 10 and Pen m 1), as well as PR-10 and profilins, among others.
of the score of the components belonging to those groups.
tera venoms), represented by the sum of the score of the components
nt components are also calculated to support the patient’s phenotyping.
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ated risks, and evaluates the “relative level of positivity” in
the context of the component family. The last issue was
implemented because the specific sIgE scores for the
inhalants can range between 0 and 100 ISU, while the
scores for the food components generally range between 0
and 10 ISU. Unfortunately, there is only one ISAC scale
(from 0 to 100 ISU). From a practical point of view, a
score of 10 ISU for Der p 1 (low level) is different from a
score of 10 ISU for Pru p 3 (a high level, compared to the
average results). The product of the IE is a raw report that
contains three different sections and subsections (Table 3).
The general strategy for ISAC result interpretation
As already mentioned, the 112 components of the ISAC
have many complex relationships, and the comprehensive
use of this knowledge may add significant value to the
ISAC interpretation. For example, each allergen (for
example, Parietaria j.), despite being represented in the
ISAC by a single “genuine” component (Par j 2), is known
to consist of other components (including Par j 3, a profilin,
and Par j 4, a polcalcin). These cross-reactive components
(belonging to other allergen sources) are present in theTable 3 Sections of the Allergenius report
1st section,
1. Headings.
2. Patient’s ID, test date and methodology used.
3. The declaration of the patient’s sensitization (and not allergy) as
4. An overview of the patient’s sensitization (genuine, cross-reactive, i
of sensitization in an uncensored population of allergic patients.
5. Some general statistical data, such as the total ISAC score (in gen
genuine and cross-reactive components, the fraction of food allerg
6. An analysis of the compatibility between the ISAC results and th
7. The patient’s phenotyping [32]: Type I, only genuine inhalant comp
inhalant components; Type III, both genuine and cross-reactive comp
constituted almost exclusively of IgE to inhalant cross-reactive compo
seems to be predictive of the immunotherapy outcome [6].
8. Warnings indicating the presence of sIgE directed at potentially
2nd section. The list of positive components.
1. IgE-positive inhalant components are described. For each compo
description of the frame structure of Allergenius are reported.
2. Positive food components are reported; in particular, the suscep
3. The list of different families of cross-reactive components, which
performs an analysis of each family, indicating whether sensitizatio
3rd section. This section is considered helpful to the doctors while managing
1. Indications of the relationships between the positive molecular c
(Table 3).
2. Some short indication of the therapy [29,30], including the removal o
(D1 and D2), grasses (G2 and 6), trees (T3 and T9), weeds (W1, W6, W21
steroids, and new-generation anti-histaminic drugs. Note that this is a b
3. An analysis of the discrepancies between the SPT, sIgE and ISACISAC. Thus, in the presence of sIgE to profilins, a cross
reaction with Parietaria j. profilin cannot be ruled out or,
even better, should be seriously considered [33]. A positive
“genuine” component is the sign of a true specific
sensitization, while the negativity of the “genuine” com-
ponent(s) excludes a specific sensitization. However, the
positivity of other cross-reactive components belonging
to other allergen sources, such as PR-10, profilins and
polcalcins, must be carefully considered in the inter-
pretation of the clinical symptoms as well as when
considering the results of the SPT and sIgE results for
extractive allergens. Similarly, some extractive components,
such as MUXF3, Phl p 4 and Jug r 2, carry cross-reactive
carbohydrate determinants (CCD), whose cross-reactivity
must be ruled out before defining their significance. Of note,
using MUXF3 to evaluate the CCD in ISAC is less sensitive
than the same test on the standard ImmunoCAP assay.
Insertion of hypertext links in the ES report
The I/O structure produced by the code is a .txt report
file, which is suitable for further elaboration by standard
word processing tools, such as MS Word. Indeed, the
initial raw text file that is generated is post-processed bythe unique result generated by the ES report.
nhalant, food, hymenoptera, etc.) and the frequency of such a distribution
eral correlating to the level of circulating total IgE), the fraction of the
ens, etc.
e diseases suffered by the patients.
onents; Type II, genuine inhalant components with a few cross-reactive
onents are represented in the Patient’s IgE profile; Type IV, the IgE profile is
nents; Type V, sIgE are specific for only food components. This classification
dangerous components [8].
nent, the characteristics listed in the
tibility to heat and pH is described.
includes many of the above-analyzed components, is reported. The IE
n to the single component(s) or to the whole family is suspected.
patients. It includes:
omponent(s) and known clinical syndrome(s) or associations are listed
f the allergen immunotherapies for most well-known allergens, such as mites
) and animals (E1 and E5), or medical therapies with bronchodilators, local
eta-version and is implemented strictly for research use only.
results to improve the reading of the complex microarray tests.
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words (such as mites, birch, Der p 1), acronyms (such as
nsLTP, PR-10, etc.) and diseases (mite-shrimp-syndrome)
into links to the www.allergenius.it site. This web site con-
tains the additional information (pictures, taxonomy, refer-
ences, etc.) that was obtained during the development of
the KB but was not inserted into the frames. Of note, differ-
ent examples of the ES report are available on this web site.
Validation of the expert system
First, an in silico validation was performed. The ES was
loaded with totally negative or totally positive ISAC files
to confirm that all routines worked appropriately. Then,
to validate the relationships between the allergens, files
with positive groups (such as mites, animals, profilins,
etc.) were assayed. Finally, 100 random results files were
generated and processed. Because, in real life, only a
maximum of 15% of the components have positive results
in poly-sensitized patients, these files were designed to
reflect this situation. Finally, clinical validation was per-
formed using two approaches. The first was to compare
100 results of the ES with the results of X-Plain, the
specific proprietary explanation software for ISAC analysis.
Then, according to Linnett [34], 10 anonymous samples
from real patients were evaluated by six allergists expert in
molecular analysis and co-authors of this study. Briefly, the
standard ISAC report, together with the clinical picture and
the results of specific IgE tests were given to the experts
together with a short questionnaire. The questionnaire
itams were 1) to identify the patient, 2) the methodology
used and 3) to describe the frequency of similar cases
in a general population of allergic patients; 4) to define
genuine and cross-reacting positive components; 5) to
define food and inhalant related positive components;
6) to define whether a co-sensitization and/or a cross-
sensitization was detectable; 7) to define whether a com-
patibility between the positive components detected and
the clinical picture was present; 8) to enlist any warning
related to potentially dangerous positive component; 9) to
enlist all positive components (food, inhalant, latex and
venoms) or component families (profilins, LTPs, PR-10
etc.); 10) to identify any potential inhalant (or pollen)-food
syndrome; 11) to give immunotherapeutic indications
based on the Douladiris [5] and Schmid-Grendlmeier [6]
indications and, finally, 12) to identify any discrepancy
between the ISAC results and other results from SPT and/
or specific IgE testing. The score was 1 when the ES and
the expert gave the same result; the score was 0 when the
expert did not answered the single question and the score
was 0.5 when the expert answered wrongly the question.
Results
The ES implemented to support the interpretation of
ISAC results was originally designed with the aim ofmimicking the behavior of a molecular allergy expert. In-
deed, an expert is expected to do more than just
discriminate between the positive and negative results. The
allergist is expected to read the ISAC results while consid-
ering the role of the allergen and component families, as
well as considering the relationships between the compo-
nents and the cross-reactivities. If possible, information
leading to the prescription of an immunotherapy and the
discrepancies between the different tests is also expected.
The ES was named Allergenius ®, and the v4.4 version
was used for these tests. The production of the report text
file requires a few tenths of a second. The time taken to
transform the raw text file into a MS Word report using
Visual Basic, during which all of the relevant words
become specific links, required a few seconds. According
to the user’s decision, the report language can be either
English or Italian, and the level of detail can be either
basic or advanced. Six different example reports (in either
Italian or English and with either a basic or advanced level
of detail) can be found on the www.allergenius.it web site.
Irrespective of the level of detail, an Allergenius report
starts with the items described in Table 3. The main
section details all of the positive components. These
include the molecule, the origin, the family, any possible
cross-reactions and any warnings related to potentially
dangerous components, such as lipid transfer proteins.
The “relative level of positivity” for each of the positive
results (as IgEs to inhalants have a range from 0 to 100
ISU, while IgEs to foods rarely exceed 10 ISU) is also
calculated. The following section details the cross-reactive
components, ordered in families, with the aim of accurately
describing these important sources of sensitization. In this
section, an attempt to discriminate the sensitization toward
one or a few of the components from the sensitization to
the whole family is made. On the basis of both statistical
and heuristic considerations, a sensitization to > 40% of the
members of the family is considered a sensitization to the
whole family. Of course, this approach cannot be applied
to all families of cross-reactive components available in
the ISAC; for example, there are only two polcalcins
(Phl p 7 and Bet v 4) and the parvalbumins (Gad c 1)
are represented by a single component. Another attempt
to define the “first sensitizer” was also implemented in
the IE. The first sensitizer is, in general, the earliest
component to which a sensitization occurs in a patient’s
life. This is normally associated with the highest ISU score.
The first member of each family that appears can be easily
identified by studies on the allergenic march [11]. Thus,
when the highest ISAC score corresponds to the member
known to appear first, this can be identified as the first
sensitizer in a given patient. Of course, the members of
families are extremely cross-reactive. For this reason, this
algorithm may, for example, indicate that Bet v 1 is the
first sensitizer in regions, such as the Mediterranean
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environments, other sensitizers that are highly homolo-
gous to Bet v 1 components, such as the hornbeam Car b
1 and oak Que a 1 components [35,36], are very frequent.
In the third and final section, three other calculated
results are available. The first is the list of syndromes or
associations related to one or more of the positive com-
ponents (Table 4). The second is a list of the therapeutic
suggestions for positive inhalant components. This is based
on the “European” approach to immunotherapy [31,32],
which limits the number of allergens to be administered.
Along this line, the algorithm recently proposed for pollens
has also been considered [5]. Finally, the discrepancies
between the SPT and/or sIgE scores and the ISAC results
[10] are also discussed. These discrepancies may be a
source of confusion for allergists only partially trained in
molecular allergy diagnosis.
Starting from the results obtained as described, the in silico
validation was performed, and all of the tests with negative
and/or positive samples had the expected results. These tests
were carried out thousands of times during the development
of the code, and the results were always the same.
Random results were also tested. For this, 100 random
ISAC results, with a frequency of up to 15% positive compo-
nents (ranging 2-17%) largely aligned with those observed in
real-life patients, were obtained. Every component was
present in these tests (median frequency 13%, range 5
-26%), and the ES identified all of the different components,
including both the genuine and cross-reactive components
and suggested the syndromes associated with the individual
components with great accuracy.
The validation with X-Plain was performed on 100
ISAC results. Of these results, 15 were negative, and the
remaining belonged to poly-sensitized patients. Even in
this validation step, all the positive, as well as the nega-
tive, components were identified correctly, and the ESTable 4 Syndromes and associations related to the
sensitization to allergens or components
Syndrome or Association Allergen or component(s)
involved
Mite Shrimp syndrome Der p 10
Mugwort chamomile association Art v 1 (?)
Birch apple syndrome Bet v 1 – Mal d 1
Latex fruit syndrome Hev b 6, Hev b 7
Cypress peach syndrome LTP
Alternaria spinach syndrome Alt a 1
Goosefoot melon association Che a 2, Che a 3
Russian thistle saffron association Not known
Wheat Dependent Exercise Induced
Anaphylaxis (WDEIA)
ω-gliadins or a high molecular
weight glutenin subunit
Pellittory pistachio association Cross reacting proteins on SDS
PAGE and immunoblotcomments were almost identical to those of X-Plain. How-
ever, because of the specific structure of Allergenius, infor-
mation that was unavailable using X-Plain were obtained.
With regard to the human experts’ opinions, the results
of the questionnaires obtained are shown in a Forest plot
(Figure 1). There was a total concordance between the ex-
perts and the ES in 10/18 issues, namely identification of
patients, of positive components and of characteristics of
components. The compatibility of the clinic with the ISAC
result and the list of warnings were considered by the ex-
perts even if few errors were made. Finally, experts had
difficulties in defining the frequency of the clinical picture,
the patient’s phenotyping, the pollen-food syndromes, the
immunotherapeutic indications and the discrepancies be-
tween the results of ISAC and those of other sIgE tests.
Notably, the experts did not identify issues that the ES
was unable to detect. However this results was condi-
tioned by the “closed” list of questions asked to the ex-
perts. Even more interestingly, only two experts were able
to correctly answer all the points of the questionnaire.
The validation procedures performed herein demon-
strated that the ES is highly capable of detecting every
positive and negative component, of distinguishing
cross- and co-sensitization and in identifying sensitization
to genuine and cross-reactive components. Allergenius
is able to process all possible ISAC results using two
different levels of detail. The basic level, compared to the
X-plain software report, adds some additional information.
This includes the analysis of cross- and co-sensitization, the
patient’s phenotype, the semi-quantitative and relative score
of each component, the consistency between the patient’s
disease and the positive component, the discrepancies be-
tween the ISAC results and other tests, the list of possible
syndromes associated with the positive components and a
proposal for therapy for inhalants. The advanced level adds
much more statistical information to the report, such as the
frequency of a given component, the median score, and the
highest level observed, among others.
Discussion
The strengths of this approach are numerous. In general,
ESs are characterized by a) the consistency and traceability
of the results compared to an individual’s interpretation;
b) the productivity gains (less expensive than an expert);
c) the performance gains (quicker than humans); and d)
the availability of the solution (can be available anytime,
anywhere). Moreover, using Flex, the structure of the
code is in plain English and is aligned with the experts’
understanding of the real world. Finally, the hierarchical
structure allows the insertion of new facts and rules with-
out significantly modifying the program. Allergenius has
other specific advantages; for example, the report language
is either English or Italian, but thanks to its structure,
other languages can be easily implemented, reducing the
Figure 1 Forest-plot of the validation results. On the horizontal axis, the percentage of correct results observed. On the vertical axis, the different
issue of the questionnaire. A black box represents the mean result for a given issue. A black box on the 100% line is indicative of “always correct” answers
to the experts’ questionnaire. The lines represent the variation of the results. A line starting from 0% means that one or more expert did not answer the
question. See the Materials and Methods section for a more detailed description of the parameters analyzed and of the methodology used.
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an ES written by MDs for MDs, special attention was
given to the construction of the report. For example,
the above-mentioned level of detail can be defined by
the user. Thus, experts will not be obliged to read that
Der p 1 is a cysteine protease or that Dermatophagoides
pt. belongs to the Pyroglyphidae family, and novices will
not be confused by too much data. If needed, further
information is available using a dedicated hypertext link.
Weaknesses are also present. For example, while the
rules from the literature were always considered true,
other rules were discussed within the group of authors:
some were widely accepted, others were not. However,
the rules were organized in such a way that they can be
modified as soon as other or more accurate rules become
available. Of course, starting from 112 different compo-
nents, the number of combinations is enormous. The
problems related to the IgE profiles are very complex, and
the advancement of molecular allergy research is very
fast. Thus, Allergenius will remain effective only under
a continuous revision process. We are also aware that
a significant number of colleagues dislike computer-
supported diagnoses. However, relevant information,
such as references, blogs, comments and mails, are often
used, making computer-supported diagnosis generally
accepted. The authors have extensively discussed whether
the code should be freely available on the internet or
should remain proprietary to the laboratory where the
ISAC is carried out. The former possibility is extremely in-
teresting; virtually all ISAC studies carried out worldwide
could be analyzed using the ES. Comments, observationsand errors could be noticed immediately, and the code
could be improved very quickly. Even more, using elemen-
tary machine-learning techniques, the rules and the know-
ledge base could be updated in real time. Nevertheless, in
the absence of a very exhaustive clinical validation, the risk
of some unknown bugs or errors cannot be ruled out. Of
course, the authors are available to receive ISAC results,
along with the SPT results, specific IgE results and a brief
sketch of the clinical history, to allow other colleagues to
evaluate and comment on the present and future Aller-
genius releases. This will represent a more in-depth and
rigorous validation not only of the rules implemented
but also of the capacity of an ES to support the inter-
pretation of results obtained by allergy molecular diag-
nostics tests.
A molecular allergy diagnosis based on microarray
technology may sometimes be a complex task due to the
large number of results available, the relationships between
the components and the rules that govern virtually every
single component. For this reason, a computer-assisted tool
based on data from the literature, international guidelines
and experts’ opinion may play a significant role, particularly
in countries where these molecular tools are only recently
available. In the present version, Allergenius is a very ad-
vanced working prototype with great possibilities of im-
provement. Allergenius could be useful in the interpretation
of molecular allergy tests, in allergen microarray diagnostics
training programs and in supporting allergists in their pro-
fession. By adopting a frame hierarchy approach, the struc-
ture based on Flex allows for real-time modification of the
knowledge base as well as the adaption to specific
Melioli et al. World Allergy Organization Journal 2014, 7:15 Page 8 of 9
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Allergists are aware that the characteristics of the 112
different components may sometimes be difficult to keep
in mind; for this reason, an ES tool could definitely be ac-
cepted by the allergist community. If not, the efforts to
build this system and the results described in this work
can still be useful to allergists to realize the large volume
of information that can be extracted from an ISAC report.
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